Parallel Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Parallel Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-199	Closed	–	–	2789
2020 Q1	$0	Buy	+199	New	+$1.48K	﹤0.01%	2738

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Parallel Advisors's RUBY Position: Q2 2020 in Review

Parallel Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2020, closing a stake of 199 shares.

Parallel Advisors first reported a position in RUBY in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 86 funds tracked by Wall St. Rank hold RUBY as of Q2 2020.

Parallel Advisors reported no remaining Rubius Therapeutics, Inc position as of Q2 2020 after selling out during the quarter.
Parallel Advisors sold 199 Rubius Therapeutics, Inc shares in Q2 2020.
Parallel Advisors first reported a position in Rubius Therapeutics, Inc in Q1 2020 and held it in 1 quarter.
Parallel Advisors's Rubius Therapeutics, Inc position peaked at $0 in Q1 2020.
86 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2020.

Based on Parallel Advisors's 13F filing for Q2 2020, filed 16 Jul 2020.